Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Nov 30, 2018 3:02pm
123 Views
Post# 29046963

RE:RE:RE:RE:corner turning

RE:RE:RE:RE:corner turningThanks for the update....particularly about NASH.

There is a lot of excitement in that space so may be some type of catalyst as I previously mentioned.

bfw



SPCEO1 wrote: I spoke with the CFO today and he was as upbeat as the corporate presentation was, so maybe the stock will be able to stay above its moving average this time. It sounds like they did have a good set of meetings with investors at the Piper confernece. I also asked about the remergance of the NASH study in the presentation and he said they have not yet figured out what they will do with that info if it is good data but there are a number of options. So, much to my surprise, we may have another positive catalyst for the stock come February or whenever the data gets released and the company lets us know how they are going to use it. Also, they thought the Bloomberg data they used (which is the number of vials sold) was close enough to relaity to be able to put it in their presentations. So, I will start focusing on that data (he said the other Bloomberg data was not as accurate). I think the corner has been turned.  

juniper88 wrote: Today TH went above the 50 day sma.  This is the third time since the downturn started about 6 months ago.  The previous 2 times were followed by further selling.  So,TH needs to hold above this level for at least a week and then start an upward trend.  Then we'll have confirmation of the corner being turned.




Bullboard Posts